➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
McKesson
Harvard Business School
McKinsey
Colorcon

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 7,579,321

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,579,321 protect, and when does it expire?

Patent 7,579,321 protects NOCTIVA and is included in one NDA.

This patent has forty-two patent family members in twenty-eight countries.

Summary for Patent: 7,579,321
Title:Pharmaceutical compositions including low dosages of desmopressin
Abstract: The present invention is directed to a pharmaceutical composition comprising 0.5 ng to 20 .mu.g desmopressin and a pharmaceutically acceptable carrier. The present invention is also directed to a pharmaceutical composition comprising desmopressin and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is effective to establish a steady plasma/serum desmopressin concentration in the range of from about 0.1 picograms desmopressin per mL plasma/serum to about 10.0 picogram desmopressin per mL plasma/serum. Articles of manufacture and methods of using the above invention are also disclosed.
Inventor(s): Fein; Seymour (New Canaan, CT)
Assignee: Reprise Biopharmaceutics, LLC (New City, NY)
Application Number:12/173,074
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,579,321
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,579,321

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Alyvant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-001 Mar 3, 2017 DISCN Yes No   Start Trial   Start Trial A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS   Start Trial
Alyvant NOCTIVA desmopressin acetate SPRAY, METERED;NASAL 201656-002 Mar 3, 2017 DISCN Yes No   Start Trial   Start Trial A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,579,321

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0210397.6May 7, 2002

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Mallinckrodt
McKesson
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.